Brincidofovir for PML

This trial tests a drug called brincidofovir to determine its effectiveness in treating progressive multifocal leukoencephalopathy (PML), a rare brain infection in individuals with weakened immune systems. The main goal is to assess whether this antiviral drug, originally approved for smallpox, can effectively treat PML. Individuals diagnosed with PML who can travel to NIH for the study may be suitable candidates. Participants will receive the drug intravenously and undergo several tests to monitor their progress. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research has shown that Brincidofovir (BCV) is generally safe. Tests with mice demonstrated that BCV did not cause harmful effects. The FDA has already approved BCV to treat smallpox, indicating it has passed safety tests for that purpose. This approval suggests potential safety for humans, although its use for treating Progressive Multifocal Leukoencephalopathy (PML) remains under investigation. While researchers continue to test the drug's safety, this background indicates a promising safety profile for BCV in treating PML.¹²³⁴⁵

Brincidofovir is unique because it offers a new approach to treating progressive multifocal leukoencephalopathy (PML), which is a rare and often fatal brain infection. Unlike current treatments that mainly focus on managing symptoms and supporting the immune system, Brincidofovir is an antiviral medication specifically designed to target the JC virus, which causes PML. Researchers are excited about this treatment because it has shown potential in other viral infections and could directly inhibit the virus responsible for PML, offering hope for more effective management of this challenging condition.

Research has shown that Brincidofovir (BCV) may help combat polyomavirus infections, based on animal studies. In mice, BCV treatment reduced viral DNA levels, indicating strong antiviral effects. Although no proven treatment exists for progressive multifocal leukoencephalopathy (PML), Brincidofovir's success against similar viruses is promising. The drug already has approval for treating smallpox, demonstrating its antiviral power. These findings support testing BCV in people with PML, especially since effective treatments for this condition are lacking. Participants in this trial will receive Brincidofovir as part of the experimental treatment arm.¹²⁶⁷⁸